StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRNXBearishEarningsnews
Materiality pending

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2024, 6:42 PM EDT1 sourcesAI-analyzed

AI summary

What happened, with direct paths to the underlying reporting

- CRNX reported a quarterly loss of $0.93 per share, missing estimates. - Revenue for CRNX was $0.64 million, missing estimates by 21.47%. - CRNX shares have gained 43% this year, outperforming the market. - Earnings estimates for CRNX are mixed, with a Zacks Rank #3 (Hold). - Investors should monitor industry outlook due to potential impact on CRNX performance. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis

  • CRNX reported a quarterly loss of $0.93 per share, missing estimates.
  • Revenue for CRNX was $0.64 million, missing estimates by 21.47%.
  • CRNX shares have gained 43% this year, outperforming the market.
  • Earnings estimates for CRNX are mixed, with a Zacks Rank #3 (Hold).
  • Investors should monitor industry outlook due to potential impact on CRNX performance.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.